Lipanthyl Supra

Fenofibrate, the active ingredient in Lipanthyl Supra, is a fibrate presented as an oral dosage form for oral use. It is used to lower elevated triglyceride levels and to improve lipid profiles in patients with mixed dyslipidemia and primary hypercholesterolemia as an adjunct therapy. GNH USA supplies Lipanthyl Supra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipanthyl Supra, a fibrate, acts on lipid metabolism disorders to improve blood lipid concentrations. Hypertriglyceridemia: reduces elevated triglyceride levels. Mixed dyslipidemia: lowers triglycerides and raises HDL‑cholesterol. Primary hypercholesterolemia (adjunct): supports statin therapy to achieve target LDL‑cholesterol levels.

Fenofibrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache or dizziness. - Muscle pain or weakness. - Elevated liver enzymes. - Skin rash or pruritus. - Increased serum creatinine.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy. - Acute liver injury or hepatitis. - Pancreatitis. - Severe allergic reactions including angioedema. - Blood dyscrasias such as neutropenia. - Unexplained fatigue or jaundice.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant laboratory parameters. Renal function: assess baseline kidney function and adjust therapy if impairment is present. Hepatic function: monitor liver enzymes regularly during treatment. Drug interactions: review concomitant medications for potential additive toxicity. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at ambient temperature: keep in the original container, protect from moisture and light.

Fenofibrate can interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Cyclosporine: increased risk of myopathy. - Gemfibrozil: additive risk of rhabdomyolysis. - High‑dose statins: heightened myopathy potential. Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect. - Antidiabetic agents: may alter glycemic control. - Thiazide diuretics: can raise serum uric acid levels.